Afficher la notice abrégée

SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

dc.contributor.authorGarcía‑Sáenz, José Ángel
dc.contributor.authorBlancas López-Barajas, María Isabel 
dc.date.accessioned2023-07-12T11:04:09Z
dc.date.available2023-07-12T11:04:09Z
dc.date.issued2023-05-06
dc.identifier.citationGarcia-Saenz, J.A., Blancas, I., Echavarria, I. et al. SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022). Clin Transl Oncol (2023). [https://doi.org/10.1007/s12094-023-03203-8]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/83639
dc.description.abstractAdvanced breast cancer represents a challenge for patients and for physicians due its dynamic genomic changes yielding to a resistance to treatments. The main goal is to improve quality of live and survival of the patients through the most appropriate subsequent therapies based on the knowledge of the natural history of the disease. In these guidelines, we summarize current evidence and available therapies for the medical management of advanced breast cancer.es_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAdvanced breast canceres_ES
dc.subjectABCes_ES
dc.subjectGuidelineses_ES
dc.subjectEndocrine therapyes_ES
dc.subjectAnti-HER2 therapyes_ES
dc.subjectIOTes_ES
dc.subjectADCes_ES
dc.titleSEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)es_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1007/s12094-023-03203-8
dc.type.hasVersionVoRes_ES


Fichier(s) constituant ce document

[PDF]
Nom:
s12094-023-03203-8.pdf
Taille:
1.415Mo
Format:
PDF
[PDF]
Nom:
CORRECTIONs12094-023-03229-y.pdf
Taille:
404.4Ko
Format:
PDF

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Atribución 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Atribución 4.0 Internacional